EPS for SeaSpine Holdings (SPNE) Expected At $-0.54; Sachem Head Capital Management LP Lifted Shire Plc (SHPG) Stake

February 11, 2018 - By Vivian Park

Analysts expect SeaSpine Holdings Corporation (NASDAQ:SPNE) to report $-0.54 EPS on March, 1.They anticipate $0.33 EPS change or 37.93% from last quarter’s $-0.87 EPS. After having $-0.58 EPS previously, SeaSpine Holdings Corporation’s analysts see -6.90% EPS growth. It closed at $10.85 lastly. It is down 6.47% since February 11, 2017 and is uptrending. It has underperformed by 10.23% the S&P500.

Sachem Head Capital Management Lp increased Shire Plc (SHPG) stake by 60% reported in 2017Q3 SEC filing. Sachem Head Capital Management Lp acquired 465,000 shares as Shire Plc (SHPG)’s stock rose 4.45%. The Sachem Head Capital Management Lp holds 1.24M shares with $189.89 million value, up from 775,000 last quarter. Shire Plc now has $36.80B valuation. The stock increased 0.95% or $1.2 during the last trading session, reaching $127.43. About 2.07 million shares traded or 58.60% up from the average. Shire plc (NASDAQ:SHPG) has risen 4.69% since February 11, 2017 and is uptrending. It has underperformed by 12.01% the S&P500.

Among 3 analysts covering SeaSpine Hldgs (NASDAQ:SPNE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SeaSpine Hldgs had 5 analyst reports since June 21, 2017 according to SRatingsIntel. Piper Jaffray maintained the shares of SPNE in report on Friday, August 18 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, September 28. The rating was maintained by BTIG Research on Tuesday, July 11 with “Buy”.

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and Internationally. The company has market cap of $145.71 million. The firm provides orthobiologics and spinal fusion hardware solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. It currently has negative earnings. The Company’s orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.

Among 25 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 20 have Buy rating, 0 Sell and 5 Hold. Therefore 80% are positive. Shire plc (ADR) had 65 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Monday, August 21 with “Buy”. Liberum Capital upgraded Shire plc (NASDAQ:SHPG) on Tuesday, November 14 to “Buy” rating. RBC Capital Markets maintained it with “Buy” rating and $21300 target in Friday, August 4 report. The firm earned “Buy” rating on Tuesday, November 3 by HSBC. The firm has “Hold” rating by HSBC given on Monday, September 26. The rating was upgraded by HSBC on Tuesday, October 27 to “Buy”. The stock of Shire plc (NASDAQ:SHPG) earned “Buy” rating by RBC Capital Markets on Monday, October 2. The firm has “Buy” rating given on Friday, September 22 by Cowen & Co. FBR Capital initiated the shares of SHPG in report on Wednesday, October 18 with “Buy” rating. Credit Suisse upgraded the stock to “Outperform” rating in Tuesday, January 12 report.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>